August 22, 2025 — Bio-Thera Solutions and STADA Arzneimittel have announced the expansion of their biosimilars partnership to include tocilizumab, a monoclonal antibody currently marketed by Roche under the brand name RoActemra®. This move builds on their existing collaboration around biosimilars, strengthening both companies’ positions in the competitive biologics market.
Building on Established Partnership
The new agreement extends the scope of the companies’ May 2024 alliance covering BAT2506, a proposed biosimilar to Simponi® (golimumab), for which the European Medicines Agency (EMA) has already accepted a marketing authorization application.
Under the expanded terms:
- Bio-Thera will continue to lead development, manufacturing, and supply of the tocilizumab biosimilar.
- STADA will gain exclusive commercialization rights across the European Union, United Kingdom, Switzerland, and selected additional markets.
This complementary structure allows Bio-Thera to focus on its strengths in biologics development and supply chain excellence, while STADA leverages its established regional presence and regulatory expertise.
Regulatory and Market Context
Advertisement
Biosimilar versions of tocilizumab have already begun to gain traction globally. In June 2024, Bio-Thera’s BAT1806, also branded as Tofidence™, secured marketing authorization in the European Union. In parallel, regulators in the United States approved multiple biosimilars during the first half of 2025, including tocilizumab, highlighting the growing acceptance and demand for cost-effective biologic alternatives.
This expansion aligns with a broader trend: payers, providers, and regulators are accelerating pathways for biosimilar adoption to increase competition, reduce healthcare costs, and improve patient access.
The collaboration has several key implications for stakeholders across the cGxP ecosystem:
Patient Access & Affordability: Introducing a biosimilar alternative to tocilizumab in major European markets could significantly lower treatment costs and broaden therapeutic availability.
Regulatory Strategy: The alliance underscores the importance of streamlined regulatory pathways and strategic partnerships to accelerate market entry while ensuring compliance.
Manufacturing & Quality: With Bio-Thera responsible for development and production, the agreement emphasizes rigorous adherence to cGMP standards, while STADA’s commercialization ensures ongoing GCP and GLP considerations across the product lifecycle.
This extended collaboration is more than a product agreement; it signals the strategic role partnerships play in shaping the future of biosimilars. By combining Bio-Thera’s biologics expertise with STADA’s regional strength in commercialization, the alliance is well positioned to deliver high-quality, affordable therapies to patients across Europe and beyond. For the global community, the deal illustrates how innovation, compliance, and partnership agility are driving the next chapter of access and sustainability in biologics.
Source: STADA, Press Release
